Ariflo COPD Long-Term Efficacy Studies Should Use Active Controls – Cmte.
Executive Summary
GlaxoSmithKline's long-term efficacy studies for Ariflo in chronic obstructive pulmonary disease should be designed as non-inferiority trials with active controls, members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested Sept. 5
You may also be interested in...
Quarterly Call Round-Up: Pfizer, GSK, Lilly Updates
Pfizer sees more savings from Pharmacia: Pfizer is now projecting "at least" $1 bil. in synergies from the Pharmacia acquisition in 2003, indicating that it expects to exceed its original target of $1 bil. in first-year savings...
Quarterly Call Round-Up: Pfizer, GSK, Lilly Updates
Pfizer sees more savings from Pharmacia: Pfizer is now projecting "at least" $1 bil. in synergies from the Pharmacia acquisition in 2003, indicating that it expects to exceed its original target of $1 bil. in first-year savings...
October User Fee Lineup Includes 7 NMEs; Many Expect “Approvable” Action
FDA enters the fourth quarter with at least 28 pending applications with October user fee deadlines, including seven new molecular entities and one new biologic